Document is current
Any future updates will be listed below
-
Authors
Wu, Katherine https://orcid.org/0000-0002-0472-0166
Vaughan, Alec J.
Bossowski, Jozef P.
Hao, Yuan
Ziogou, Aikaterini https://orcid.org/0009-0000-0028-6748
Kim, Seon Min
Kim, Tae Ha https://orcid.org/0000-0001-5182-8578
Nakamura, Mari N.
Pillai, Ray https://orcid.org/0000-0002-8335-3463
Mancini, Mariana
Rajalingam, Sahith
Han, Mingqi https://orcid.org/0000-0003-2070-5967
Nakamura, Toshitaka
Wang, Lidong
Chung, Suckwoo
Simeone, Diane
Shackelford, David https://orcid.org/0000-0002-8270-898X
Kang, Yun Pyo https://orcid.org/0000-0002-1149-0880
Conrad, Marcus https://orcid.org/0000-0003-1140-5612
Papagiannakopoulos, Thales https://orcid.org/0000-0002-2251-1624
- License Information
-
More Information
Article History
Received: 25 August 2024
Accepted: 6 October 2025
First Online: 5 November 2025
Competing interests
: T.P. received funding from Pfizer Medical Education Group, Dracen Pharmaceuticals, Kymera Therapeutics, Bristol Myers Squibb and Agios Pharmaceuticals not related to the submitted work. M.C. is a co-founder and shareholder of ROSCUE Therapeutics GmbH. M.C. and T.N. have filed a patent application (WO2024115673A1) for some of the FSP1 inhibitor compounds described here. The other authors declare no competing interests.
